Clinical validation of the novel CLIA-CA-62 assay efficacy for early-stage breast cancer detection
BackgroundWithout organized screening programs up to 60-70% of breast cancers are diagnosed at advanced stages that have significantly lower five-year survival rate and poorer outcomes, which is a serious global public health problem. The purpose of the blind clinical study was the assessment of the...
Main Authors: | Marina Sekacheva, Alexander Boroda, Anastasia Fatyanova, Alexander Rozhkov, Nikolai Bagmet |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1009863/full |
Similar Items
-
Practical application of the CA-62 tumor marker in the initial diagnosis of oncological disease of epithelial origin: assistance to the doctor in interpreting the results
by: Janneta R. Tcherkassova, et al.
Published: (2023-06-01) -
Diagnostic significance of CA-62 cancer antigen for early detection and differential diagnosis of non-small cell lung cancer: results of the blind clinical trials
by: Janneta R. Tcherkassova, et al.
Published: (2023-05-01) -
A case of ductal carcinoma in situ (DCIS) with markedly elevated CA15-3 levels requiring 2 years of diagnosis
by: Mutsumi Fujimoto, et al.
Published: (2023-12-01) -
Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?
by: Ezra Hahn, et al.
Published: (2023-06-01) -
Ductal carcinoma in situ of the breast arising in a solitary intraductal papilloma
by: Noor Badrawi, MD, et al.
Published: (2023-02-01)